Meloxicam injection gets approval for management of moderate-severe pain

  • Food and Drug Administration

  • curated by Kelli Whitlock Burton
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Meloxicam injection (Baudax Bio, Inc.) for adults with moderate to severe pain has received approval from the FDA.

Why this matters

  • Meloxicam injection is the only available 24-hour intravenous (IV) cyclooxygenase-2 preferential NSAID.
  • EMA information on meloxicam-based drugs is available here.

Key points

  • For use with or without other non-NSAID analgesics.
  • Dosage: 30 mg once daily by IV bolus injection over the course of 15 seconds.
  • Meloxicam injection alone is not recommended for acute pain.
  • Contraindicated with a history of asthma, urticaria, or other allergic-type reactions after receiving aspirin or other NSAIDs.
  • Concomitant use with analgesic doses of aspirin is not recommended.
  • Approval based on 2 randomized, double-blind, placebo-controlled, phase 3 trials in patients with postoperative pain who received meloxicam injection or placebo once daily:
    • In 201 adults who underwent bunionectomy, meloxicam injection was associated with a significant decrease in the sum of the pain intensity differences (SPID) at 48 hours (P=.0034), longer time to first dose of rescue medication (P=.0076), and fewer patients using rescue medication (P<.001>
    • In 219 adults who underwent abdominoplasty, meloxicam injection was associated with a significant decrease in SPID (P=.0145) and fewer patients using rescue medication at 24-48 hours (P=.0014).
  • Most common adverse events include constipation, increased gamma-glutamyl transferase, and anemia.

Prescribing information